RenovoRx, Inc. filed a Form 8-K on November 20, 2026, disclosing the appointment of Richard Stark as a director effective November 18, 2026, along with the compensatory arrangements associated with his appointment.
Key Highlights
- Board expanded: The Board approved an increase in size from six to seven directors, with Richard Stark appointed to fill the resulting vacancy.
- Effective date: The appointment was effective November 18, 2026.
- Initial equity award: Stark received 128,824 options to purchase shares of Common Stock with an aggregate grant date fair value of $120,000 and a per share exercise price of $1.12.
- Annual cash retainer: Stark will receive an annual cash retainer of $40,000, payable quarterly in arrears and prorated for any partial quarter of service.
- Prior consulting role ended: A Consulting Termination Agreement dated November 11, 2026, terminated the prior Consulting Agreement effective November 15, 2026, with 12,000 unvested options forfeited by Stark.
- Independent director determination: The Board determined that Stark qualifies as an independent director in accordance with Nasdaq Stock Market LLC requirements.
Richard Stark's Appointment and Compensation at RenovoRx
According to the filing, RenovoRx, Inc. (NASDAQ:RNXT) disclosed that its Board of Directors approved the expansion of the Board from six to seven members and appointed Richard Stark, age 62, to fill the newly created vacancy. The appointment became effective November 18, 2026. The filing states that Stark has more than 30 years of leadership experience in the medical technology industry and currently serves as Chief Executive Officer of Innoblative Designs, Inc. and as Founder and Managing Member of MedTech Angels, among other roles.
Prior to his appointment as a director, the filing states that Stark had served as a consultant to the Company since December 5, 2024, acting as its Strategic Commercial Advisor. His consulting arrangement was terminated pursuant to a Consulting Termination Agreement dated November 11, 2026, effective November 15, 2026. At that time, 12,000 unvested options to purchase shares of Common Stock were forfeited. The filing notes that Stark received no cash compensation under the consulting arrangement, only options.
Upon his appointment, the filing discloses that Stark received an Initial Award of 128,824 options to purchase shares of Common Stock with an aggregate grant date fair value of $120,000. The per share exercise price is $1.12, equal to the closing price of the Common Stock on the grant date. The options vest at a rate of 1/36th per month and have a term of ten years. The filing also states that Stark will receive an annual cash retainer of $40,000 and will be eligible for an automatic grant of options with a grant date fair value of $70,000 in the aggregate on October 1, 2027, prorated based on days elapsed from November 18, 2026 to October 1, 2027.
What Was Disclosed
RenovoRx filed an 8-K on November 20, 2026, reporting the appointment of Richard Stark to its Board of Directors effective November 18, 2026, the termination of his prior consulting agreement, and the compensatory arrangements established under the company's Outside Director Compensation Policy.




Please wait processing your request...